Autobio Diagnostics Co

Autobio Diagnostics Co Total Assets

The Total Assets of Autobio Diagnostics Co (603658.SS) as of Oct 20, 2026 is 12.29 B CNY. In the previous year, Total Assets was 11.88 B CNY — a change of 3.49% (higher).

Total Assets

12.29 BCNY

YoY

3.49%

Last updated:

Total Assets of Autobio Diagnostics Co is 2025 12.29 B CNY. Total Assets of Autobio Diagnostics Co was 2024 11.88 B CNY. It decreases by 3.49% higher compared to the previous year.

The Autobio Diagnostics Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
2.66 B CNY
Jan 1, 2019
4.26 B CNY
Jan 1, 2020
8.14 B CNY
Jan 1, 2021
9.23 B CNY
Jan 1, 2022
10.47 B CNY
Jan 1, 2023
11.55 B CNY
Jan 1, 2024
11.88 B CNY
Jan 1, 2025
12.29 B CNY
The Autobio Diagnostics Co Total Assets history
YEARTotal AssetsYoY
12.29 BCNY+3.49%
11.88 BCNY+2.78%
11.55 BCNY+10.33%
10.47 BCNY+13.43%
9.23 BCNY+13.46%
8.14 BCNY+91.15%
4.26 BCNY+60.24%
2.66 BCNY+21.45%
2.19 BCNY+20.09%
1.82 BCNY+92.63%
945.56 MCNY+45.02%
652.03 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co., Ltd. generates revenue through the sale of in vitro diagnostic reagents and instruments, including gnostic products, microbiology detection products, and related devices. The company's immunodiagnostic products consist of microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. Microbiology detection products feature training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers, all distributed within domestic markets. The firm targets domestic healthcare providers and laboratories as primary buyers of its diagnostic reagents and instruments. Its core products serve clinical diagnostics needs for infectious disease testing, microbial identification, and immune response analysis. The company's product portfolio emphasizes domestic market distribution, with no mention of international sales channels or export activities. Autobio Diagnostics' revenue streams are derived from the manufacturing and distribution of diagnostic reagents, instruments, and related devices. The company focuses on domestic market penetration through its product range, which includes specialized reagents for microbiology and immunodiagnosis. No additional revenue sources such as service contracts or software licensing are indicated in the business description. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Total Assets of Autobio Diagnostics Co is 12.29 B CNY in 2025.

Total Assets of Autobio Diagnostics Co changed from 11.88 B CNY to 12.29 B CNY, representing a 3.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Autobio Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Autobio Diagnostics Co

All Key Metrics — Autobio Diagnostics Co